Skip to search formSkip to main contentSkip to account menu

eniluracil

Known as: 5-ethynyl-2,4(1H,3H)-Pyrimidinedione, 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl-, ethynyluracil 
An orally-active fluoropyrimidine analogue. Eniluracil inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and… 
National Institutes of Health

Related topics

Related topics

7 relations
Dihydropyrimidine dehydrogenaseanalogs & derivativesethynyluracil/fluorouracil

Broader (2)

Enzyme InhibitorsUracil

Narrower (2)

GW776GW776C85

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Dynamic metabolic labeling of DNA in vivo with arabinosyl nucleosides
Commonly used metabolic labels for DNA, including 5-ethynyl-2′-deoxyuridine (EdU) and BrdU, are toxic antimetabolites that cause… 
Highly Cited
2006
Highly Cited
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Highly Cited
2002
Highly Cited
2002
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable… 
Review
2000
Review
2000
New directions in the treatment of colorectal cancer: a look to the future.
Highly Cited
1999
Highly Cited
1999
Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
PURPOSE To determine the effect of eniluracil on colorectal tumor dihydropyrimidine dehydrogenase (DPD) activity. PATIENTS AND… 
Review
1999
Review
1999
Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Dihydropyrimidine dehydrogenase (DPD) is the initial, rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU). DPD has an… 
Highly Cited
1998
Highly Cited
1998
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
PURPOSE To determine the highest dose of fluorouracil (5-FU) that could be safely administered with Eniluracil (776C85; Glaxo… 
Highly Cited
1995
Highly Cited
1995
Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil.
5-Ethynyluracil (5-EU; 776C85) is a potent mechanism-based inactivator of dihydropyrimidine dehydrogenase that improves the… 
1994
1994
5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs.
Highly Cited
1992
Highly Cited
1992
Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)